1. An inhibitory immunoreceptor, Allergin-1, suppresses FITC-induced type 2 contact hypersensitivity.
- Author
-
Almeida MS, Shibagaki S, Tahara-Hanaoka S, Shibayama S, and Shibuya A
- Subjects
- Animals, CD4-Positive T-Lymphocytes cytology, Dendritic Cells cytology, Dinitrofluorobenzene chemistry, Female, Hypersensitivity, Immediate, Interleukin-10 biosynthesis, Interleukin-13 biosynthesis, Interleukin-5 biosynthesis, Mice, Mice, Inbred BALB C, Receptors, Immunologic metabolism, Dendritic Cells metabolism, Dermatitis, Contact metabolism, Fluorescein-5-isothiocyanate chemistry, Receptors, Immunologic physiology, Skin metabolism
- Abstract
Although allergic contact dermatitis (ACD) is the most common T cell-mediated inflammatory responses against an allergen in the skin, the pathogenesis of ACD remains incompletely understood. In the sensitization phase in ACD, hapten-bearing dermal dendritic cells (DCs) play a pivotal role in the transport of an antigen to the lymph nodes (LNs), where they present the antigen to naïve T cells. Here we report that Allergin-1, an inhibitory immunoreceptor containing immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region, is highly expressed on dermal DCs. Mice deficient in Allergin-1 exhibited exacerbated fluorescein isothiocyanate (FITC)-induced type 2 contact hypersensitivity (CHS) such as ear swelling and skin eosinophilia. Allergin-1-deficient mice also showed larger numbers of CD4
+ T cells and FITC-bearing DCs and greater expressions of type 2 cytokines, including IL-5, IL-10 and IL-13, in the draining LNs than did wild type mice. In sharp contrast, Allergin-1-deficient mice showed comparable level of type 1 CHS induced by 2,4-dinitrofluorobenzene (DNFB). These results suggest that Allergin-1 on dermal DC inhibits type 2, but not type 1, immune responses in the sensitization phase of CHS., Competing Interests: Declaration of competing interest This research was funded in part by Ono Pharmaceutical Co., Ltd. S. Shibayama is an employee of Ono Pharmaceutical Co., Ltd. The sponsor had no control over the interpretation, writing, or publication of this work., (Copyright © 2021 Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF